Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The 'Cancer Biomarkers Market: Industry Trends and Global Forecasts 2024-2035: Distribution by Type of Biomarker, Type of Cancer and Key Geographical Regions' report has been added to ResearchAndMarkets.com's offering. The cancer biomarker market size is projected to grow from $28.6 billion in 2024 to $46.7 billion by 2035, representing a CAGR of 5% during the forecast period from 2024 to 2035.

都柏林，2024年5月3日（环球通讯社）--“癌症生物标志物市场：2024-2035年行业趋势和全球预测：按生物标志物类型、癌症类型和关键地理区域的分布”报告已添加到ResearchAndMarkets.com的产品中。癌症生物标志物市场规模预计将从2024年的286亿美元增长到2035年的467亿美元，在2024-2035年的预测期内复合年增长率为5%。

Over the last couple of decades, the healthcare market has witnessed the entry of several advanced and effective treatment options for cancer; these include a variety of targeted therapies, immunotherapies and certain anti-cancer vaccines as well. However, clinical cancer research is still plagued by high failure rates, various drug / therapy-related limitations, and treatment-based adverse effects, some of which have been proven to be fatal.

在过去的几十年中，医疗保健市场见证了几种先进有效的癌症治疗选择的进入；这些包括各种靶向疗法，免疫疗法和某些抗癌疫苗。然而，临床癌症研究仍然受到高失败率，各种药物/治疗相关限制以及基于治疗的不良反应的困扰，其中一些已被证明是致命的。

A prominent concern is associated with deciding the type of treatment option to be used for a specific cancer. Patients suffering from a singular type of cancer, who may be at the same stage of the disease, have been demonstrated to exhibit different molecular profiles, and thereby, may respond differently to recommended drug / therapy types.

一个突出的问题是决定用于特定癌症的治疗选择类型。患有单一类型癌症的患者可能处于疾病的同一阶段，已被证明表现出不同的分子特征，因此可能对推荐的药物/治疗类型有不同的反应。

In order to address this concern, pharmaceutical developers and healthcare professionals have adopted a more personalized approach to disease diagnosis and treatment. This personalized approach has also been referred to as oncology precision medicine. Over time, several molecular markers have been identified and characterized, and many have been validated for use in making important treatment-related decisions.

为了解决这一问题，制药开发商和医疗保健专业人员采用了更个性化的疾病诊断和治疗方法。这种个性化的方法也被称为肿瘤学精准医学。随着时间的推移，已经鉴定和表征了几种分子标记，并且许多已经被验证用于做出重要的治疗相关决策。

The role of single analyte biomarkers, such as PD-L1, BRAF, and EGFR, has been well-established across multiple cancer indications. However, owing to .

单一分析物生物标志物（如PD-L1，BRAF和EGFR）的作用已在多种癌症适应症中得到确立。但是，由于。

Attachment

附件

Global Cancer Biomarkers Market

全球癌症生物标志物市场